β-catenin在大肠癌原发灶和转移淋巴结表达的比较研究  

Comparative Study on Expression of β-catenin in Hunman Advanced Colorectal Carcinoma and Metastatic Lymph Nodes

作　　者：李晓宁[1] 刘津[1] 张国建[1] 赵晶[1] 宋志岗[1] 王凤安[1] 

机构地区：[1]河北医科大学第二医院胃肠外科,河北石家庄050000

出　　处：《昆明医学院学报》2010年第4期54-61,65,共9页Journal of Kunming Medical College

基　　金：河北省自然科学基金资助项目(2005000762)

摘　　要：目的检测大肠癌及其转移淋巴结中β-连接素(β-catenin,β-cat)蛋白及mRNA表达,讨论β-catenin的表达与大肠癌生物学行为的关系,为针对大肠癌诊断和治疗的可能新方法提供理论依据.方法采用免疫组织化学染色,蛋白免疫印记(Western Blot),逆转录-多聚合酶链反应(RT-PCR)等方法联合检测并比较45例大肠癌患者原发灶和转移淋巴结中β-catenin表达情况,并对其在转移淋巴结内癌细胞再表达的机理进行分析.结果β-cat在转移淋巴结癌细胞中的再表达与肿瘤细胞的分化程度、组织学类型密切相关.(1)免疫组化结果显示:在45例大肠癌原发灶中80%(36/45)β-cat不正常表达,40%(18/45)大肠癌转移淋巴结中β-cat再表达阳性.其中高中分化腺癌转移淋巴结内癌细胞β-cat再表达阳性率为54.2%(13/24),而低分化腺癌为23.8%(5/21),高中分化腺癌相对于低分化癌更易出现β-catenin的再表达阳性(P<0.05);在管状及乳头状腺癌β-catenin在转移淋巴结癌细胞中的再表达阳性率为35.7%(10/28),而在粘液腺癌则为47.1%(8/17,P<0.05).β-cat在转移淋巴结内癌细胞的再表达与肿瘤部位、浸润深度以及患者的性别和年龄无关;(2)RT-PCR结果显示,45例原发灶组织及相应转移淋巴结均检测到不同程度的β-cat基因表达.β-catmRNA在大肠癌的表达量为(0.724±0.006),明显低于正常大肠粘膜表达量(0.785±0.017,t=21.066,P<0.01);β-catmRNA在大肠癌转移淋巴结表达量明显高于大肠癌原发灶表达量,但低于正常大肠粘膜表达量;结合临床病理资料分析,高中分化大肠癌转移淋巴结中β-cat mRNA表达量高于低分化大肠癌转移淋巴结,管状腺癌转移淋巴结中β-cat mRNA表达量高于粘液腺癌转移淋巴结;(3)Western Blot结果显示:与25例均表达β-cat的正常大肠粘膜相比,45例原发肿瘤组织中41例检测到不同程度的β-cat表达,4例未表达:41例表达β-cat的原发肿瘤组织中其相应转移淋巴结中�Objective To investigate the expression of β-catenin mRNA and protein in hunman advanced colorectal cancer and their metastatic lymph nodes,discuss the correlation between the expression of β-catenin and the biological behaviour of colorectal cancer,and explore a new possible target on molecular level to diagnose and treat colorectal cancer.Methods The methods of immunohistochemical staining,semiquantitative RT-PCR and western blot were used to detect and compare the expressions of β-cat mRNA and protein in 45 cases of human advanced colorectal cancer and their metastatic lymph nodes.And the mechanism by wich β-cat reexpress in metastatic lymph nodes of colorectal cancer was explored.Results The re-expression level of β-cat in metastatic lymph nodes was closely related to the differentiating degree and histological type of tumor.（1） Immunohistochemical results：the abnormal expression rate of β-cat was 80%（36/45） in 45 primary tumors of human advanced colorectal cancers,and the re-expression rate of β-cat in metastatic lymph nodes was 40%（18/45） .The re-expression rate ofβ-cat in well-differentiated colorectal cancer was significantly higher than that in poorly differentiated,54.2%（13/24） versus 23.8%（5/21） .The re-expression rate of β-cat in metastatic lymph nodes of tubular or papillary adenocarcinoma and mucinous adenocarcinoma was 35.7%（10/28） and 47.1%（8/17） ,respectively.The re-expression rate of β-cat in metastatic lymph nodes was independent with the tumor location,invasion depth,and the gender and age of patients.（2） RT-PCR results：There were different expression levels ofβ-cat mRNA in 45 cases of hunman advanced colorectal cancers and their metastatic lymph nodes.The relative expression value of β-cat mRNA in colorectal cancers was（0.724±0.006） ,which was significantly lower than that in the normal colorectal mucosa（0.785±0.017,t=21.066,P〈0.01） .The relative expression value of β-cat mRNA in metastatic lymph nodes was significantly higher than

关 键 词：大肠癌 转移淋巴结 免疫组化 蛋白免疫印记 逆转录-多聚合酶链反应 再表达 

分 类 号：R730.23[医药卫生—肿瘤]